Search results
Results from the WOW.Com Content Network
McKesson Europe AG (formerly Celesio AG, previously Gehe AG), with its headquarters in Stuttgart, Germany, is a leading international wholesale and retail company and provider of logistics and services in the pharmaceutical and healthcare sectors. The company had around 37,000 employees at the end of the 2019 financial year (31 March 2019) and ...
McKesson ANZ is a fully owned subsidiary of McKesson Corporation. McKesson expanded its footprint in Australia and New Zealand by acquiring Emendo in November 2012. [61] McKesson ANZ develops and sells healthcare optimization services and software. The company has traditionally been focused on the public markets in Australia and New Zealand.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Donate
Vitusapotek is a chain of 300 pharmacies in Norway owned and run by Norsk Medisinaldepot, a subsidiary of McKesson Europe. The pharmacy chain is based in Oslo, and is the second largest in Norway, after Apotek1. The chain was established in 2001 after the deregulation of the pharmacy market in Norway.
McKesson UK rebranded as Hallo Healthcare Group and in November 2023, confirmed the sale of its 1,054 LloydsPharmacy high street and community pharmacy branches to new owners, either individually or in regional groups. [15] This saved 6,500 branch jobs and ensured that pharmacy services remain available in communities across the UK.
This page was last edited on 25 February 2018, at 07:43 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
In 2005, Hammergren was elected to Hewlett-Packard's board of directors. [17] Hammergren served until 2013 when he left the board. [18] New York City's public pension funds supported the efforts to oust Hammergren and G. Kennedy Thompson because of their support for the company's 2011 acquisition of British software maker Autonomy and "their failure to protect investors from costly, misguided ...